![]() |
6th ESACP Congress, Heidelberg, April 7-11, 1999 |
A099
Recent advances in pulmonary imaging (LIFE) have made the detection and
localization of early cancers and their precursors much more likely.
The ability to localize and detect these lesions in subjects and follow
specific sites over time gives one the opportunity to modify the early
development of lung cancer by chemopreventive methods.
The gold standard for determining a subject's status is the visual
interpretation of biopsies. Given the reproducibility of visual pathology
grading of bronchial biopsies, there exists a need to quantitate the
observable morphometric changes. To this end, we used a quantitative
microscopy system to quantitate the morphometric characteristics of
bronchial biopsy sections to use as an intermediate biomarker. This
methodology is described elsewhere at the conference. This intermediate
biomarkers has been applied to several Sialor and Retinol chemoprevention
studies. Additionally this biomarker enables one to correlate quantitative
sputum cytology approaches with quantitative histological results. The
intent is to use quantitative sputum cytology as an enrollment criteria
for future chemoprevention and lung cancer management trials. Two different
quantitative sputum cytology training methods which use different definitions
of truth will be compared. Supported by NIH Grants #CN-45597-63 &
#U01 CA 68381-01.
MORPHOMETRIC QUANTITATION OF BRONCHIAL BIOPSIES AS INTERMEDIATE ENDPOINT
BIOMARKERS FOR LUNG CANCER CHEMOPREVENTION
MacAulay C, Klein-Parker H, Leriche J, Gazdar A *, Guillaud M,
Dawe C, Payne P, Korbelik J, Palcic B, Lam S
Cancer Imaging, BC Cancer Agency, Vancouver, Canada, * University
of Texas, Dallas, USA